Stroke occurs due to interruptions in the blood supply to brain, either due to the rupture or blockage of blood vessels, leading to the death of brain cells. Stroke is one of the leading cause of death worldwide, with higher prevalence in the old age population. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. Research Beam Model: Research Beam Product ID: 242574 5370 USD New
Stroke Management Market by Type (Diagnostics, and Therapeutics) and by Application (Ischemic Stroke, and Haemorrhagic Stroke) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

Stroke Management Market by Type (Diagnostics, and Therapeutics) and by Application (Ischemic Stroke, and Haemorrhagic Stroke) - Global Opportunity Analysis and Industry Forecast, 2017-2023

 
  • Category : Healthcare
  • Published On : November  2017
  • Pages : 187
 
 

Stroke occurs due to interruptions in the blood supply to brain, either due to the rupture or blockage of blood vessels, leading to the death of brain cells. Stroke is one of the leading cause of death worldwide, with higher prevalence in the old age population. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centres for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around $34 billion each year in U.S. Hence, there is an impending need for early diagnostic devices and therapeutics to prevent deaths from stroke. The major factors driving the stroke diagnostics and therapeutics market are large patient pool along with rising aging population. The patients at risk of developing stroke, mainly those suffering from hypertension, atrial fibrillation and coronary heart diseases, would further fuel the market growth. Other factors leading to market growth are rising incidences of diabetes and large number of tobacco users. However, high cost of treatment and lack of transparent reimbursement scenario, are likely to restrict the market growth.

The global stroke diagnostic and therapeutic market, is segmented on the basis of type, application and geography. According to type, the market is segmented into diagnostics and therapeutics. Diagnostic market is further sub-segmented into Computed Tomography Scan (CT scan), Magnetic Resonance Imaging (MRI), Carotid Ultrasound, Cerebral Angiography, Electrocardiography, Echocardiography and others. Therapeutic market is further sub-segmented into Tissue Plasminogen Activator, Anticoagulant, Antiplatelet and Antihypertensive. The market is also segmented on the basis of application into Ischemic Stroke and Haemorrhagic Stroke. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA. 

Product launch is one of the few strategies adopted by leading market players. For instance, In March, 2015, FDA has approved WATCHMAN, a left atrial appendage closure device designed to prevent stroke in patients of atrial fibrillation. Silk Road Medical, Inc. has launched an Anti-Stroke Enroute Device, a transcarotid neuroprotection system, designed to access the common carotid artery by minimally invasive technique. The companies profiled in this report include, Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Cordis Corporation, Koninklijke Philips N.V., GE Healthcare, Siemens AG, Stryker Corporation, Genentech, Inc. and Merck & Co., Inc.

KEY MARKET BENEFITS: 

  • Comprehensive analysis of the factors that drive and restrict the growth of the global stroke diagnostics and therapeutics market is provided in the report

  • The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities

  • An in-depth analysis of key segments of the market demonstrate the type of stroke diagnostics and therapeutics that are currently being used along with the variants that would gain prominence in future

  • SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

  • Region-wise stroke diagnostics and therapeutics market conditions are comprehensively analysed in the report

KEY MARKET SEGMENTS:

The global stroke diagnostics and therapeutics market is segmented below:

  • Global Stroke Diagnostics and Therapeutics Market - By Type

    • Diagnostics

      • Computed tomography Scan (CT scan)

      • Magnetic resonance imaging (MRI)

      • Carotid Ultrasound

      • Cerebral Angiography

      • Electrocardiography 

      • Echocardiography

      • Others

    • Therapeutics

      • Tissue Plasminogen Activator

      • Anticoagulant

      • Antiplatelet

      • Antihypertensive

  • Global Stroke Diagnostics and Therapeutics Market - By Application

    • Ischemic Stroke

    • Haemorrhagic Stroke 

  • Global Stroke Diagnostics and Therapeutics Market - By Geography

    • North America

    • Europe

    • Asia-Pacific

    • LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYER POSITIONING, 2017
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Growth in incidence of cardiac disorders
3.5.1.2. Increase in geriatric population
3.5.1.3. Rise in patient awareness

3.5.2. Restraints

3.5.2.1. Limited insurance coverage and high cost of devices

3.5.3. Opportunities

3.5.3.1. Improvement in healthcare infrastructure in emerging nations

CHAPTER 4 STROKE MANAGEMENT MARKET, BY TYPE

4.1. OVERVIEW
4.2. DIAGNOSTICS

4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Computed tomography scan (CT Scan)

4.2.3.1. Market size and forecast

4.2.4. Magnetic resonance imaging (MRI)

4.2.4.1. Market size and forecast

4.2.5. Carotid ultrasound

4.2.5.1. Market size and forecast

4.2.6. Cerebral angiography

4.2.6.1. Market size and forecast

4.2.7. Electrocardiography

4.2.7.1. Market size and forecast

4.2.8. Echocardiography

4.2.8.1. Market size and forecast

4.2.9. Other diagnostics

4.2.9.1. Market size and forecast

4.3. THERAPEUTICS

4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Tissue plasminogen activator

4.3.3.1. Market size and forecast

4.3.4. Anticoagulant

4.3.4.1. Market size and forecast

4.3.5. Antiplatelet

4.3.5.1. Market size and forecast

4.3.6. Antihypertensive

4.3.6.1. Market size and forecast

CHAPTER 5 STROKE MANAGEMENT MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ISCHEMIC STROKE

5.2.1. Market size and forecast

5.3. HEMORRHAGIC STROKE

5.3.1. Market size and forecast

CHAPTER 6 STROKE MANAGEMENT MARKET, BY REGION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. NORTH AMERICA

6.2.1. Key market trends and opportunities
6.2.2. Market size and forecast
6.2.3. U.S. market size and forecast
6.2.4. Canada market size and forecast
6.2.5. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends and opportunities
6.3.2. Market size and forecast
6.3.3. Germany market size and forecast
6.3.4. France market size and forecast
6.3.5. UK market size and forecast
6.3.6. Italy market size and forecast
6.3.7. Spain market size and forecast
6.3.8. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends and opportunities
6.4.2. Market size and forecast
6.4.3. Japan market size and forecast
6.4.4. China market size and forecast
6.4.5. Australia market size and forecast
6.4.6. India market size and forecast
6.4.7. South Korea market size and forecast
6.4.8. Taiwan market size and forecast
6.4.9. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. Market size and forecast
6.5.3. Brazil market size and forecast
6.5.4. Turkey market size and forecast
6.5.5. Saudi Arabia market size and forecast
6.5.6. South Africa market size and forecast
6.5.7. Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1. ABBOTT LABORATORIES

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. B. BRAUN MELSUNGEN AG

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BOSTON SCIENTIFIC CORPORATION

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments

7.4. BRISTOL-MYERS SQUIBB COMPANY

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. CARDINAL HEALTH, INC.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. GE HEALTHCARE (A HEALTHCARE DIVISION OF GE COMPANY)

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments

7.7. GLAXOSMITHKLINE PLC

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. MEDTRONIC PLC

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. MERCK & CO., INC.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. SIEMENS AKTIENGESELLSCHAFT (SIEMENS HEALTHCARE)

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 2. GLOBAL STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY TYPE, 2016-2023 ($MILLION)
TABLE 3. STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 4. GLOBAL STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY TYPE, 2016-2023 ($MILLION)
TABLE 5. STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY REGION, 2016-2023 ($MILLION)
TABLE 6. GLOBAL STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 7. STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY REGION, 2016-2023 ($MILLION)
TABLE 8. STROKE MANAGEMENT MARKET FOR HEMORRHAGIC STROKE, BY REGION, 2016-2023 ($MILLION)
TABLE 9. STROKE MANAGEMENT MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 10. NORTH AMERICA STROKE MANAGEMENT MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 11. NORTH AMERICA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12. NORTH AMERICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 13. U.S. STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 14. U.S. STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 15. CANADA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 16. CANADA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17. MEXICO STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 18. MEXICO STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 19. EUROPE STROKE MANAGEMENT MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 20. EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 21. EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 22. GERMANY STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 23. GERMANY STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 24. FRANCE STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 25. FRANCE STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 26. UK STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 27. UK STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. ITALY STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 29. ITALY STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 30. SPAIN STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 31. SPAIN STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 32. REST OF EUROPE STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 33. REST OF EUROPE STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 35. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 36. ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. JAPAN STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 38. JAPAN STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. CHINA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. CHINA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. AUSTRALIA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 42. AUSTRALIASTROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. INDIA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. INDIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. SOUTH KOREA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 46. SOUTH KOREA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 47. TAIWAN STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 48. TAIWAN STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. LAMEA STROKE MANAGEMENT MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 52. LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 53. LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 54. BRAZIL STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 55. BRAZIL STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 56. TURKEY STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 57. TURKEY STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 58. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 59. SAUDI ARABIA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 60. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 61. SOUTH AFRICA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 62. REST OF LAMEA STROKE MANAGEMENT MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 63. REST OF LAMEA STROKE MANAGEMENT MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 64. ABBOTT: COMPANY SNAPSHOT
TABLE 65. ABBOTT: OPERATING SEGMENTS
TABLE 66. ABBOTT: PRODUCT PORTFOLIO
TABLE 67. B BRAUN: COMPANY SNAPSHOT
TABLE 68. B BRAUN: OPERATING SEGMENTS
TABLE 69. B BRAUN: PRODUCT PORTFOLIO
TABLE 70. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 71. BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 72. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 73. BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 74. BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 75. BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 76. CARDINAL HEALTH: COMPANY SNAPSHOT
TABLE 77. CARDINAL HEALTH: OPERATING SEGMENTS
TABLE 78. CARDINAL HEALTH: PRODUCT PORTFOLIO
TABLE 79. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 80. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 81. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 82. GSK: COMPANY SNAPSHOT
TABLE 83. GSK: OPERATING SEGMENTS
TABLE 84. GSK: PRODUCT PORTFOLIO
TABLE 85. MEDTRONIC: COMPANY SNAPSHOT
TABLE 86. MEDTRONIC: OPERATING SEGMENTS
TABLE 87. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 88. MERCK: COMPANY SNAPSHOT
TABLE 89. MERCK: OPERATING SEGMENTS
TABLE 90. MERCK: PRODUCT PORTFOLIO
TABLE 91. SIEMENS: COMPANY SNAPSHOT
TABLE 92. SIEMENS: OPERATING SEGMENTS
TABLE 93. SIEMENS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES, 2014-2017 (%)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2017
FIGURE 5. TOP PLAYER POSITIONING: STROKE MANAGEMENT MARKET, 2017
FIGURE 6. POPULATION AGED 65 AND OVER BY REGION: 2015, 2030, AND 2050
FIGURE 7. STROKE MANAGEMENT MARKET FOR DIAGNOSTICS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 8. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR COMPUTED TOMOGRAPHY SCAN, 2016-2023 ($MILLION)
FIGURE 9. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), 2016-2023 ($MILLION)
FIGURE 10. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR CAROTID ULTRASOUND, 2016-2023 ($MILLION)
FIGURE 11. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR CEREBRAL ANGIOGRAPHY, 2016-2023 ($MILLION)
FIGURE 12. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR ELECTROCARDIOGRAPHY, 2016-2023 ($MILLION)
FIGURE 13. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR ECHOCARDIOGRAPHY, 2016-2023 ($MILLION)
FIGURE 14. GLOBAL DIAGNOSTICS STROKE MANAGEMENT MARKET FOR OTHER DIAGNOSTICS, 2016-2023 ($MILLION)
FIGURE 15. STROKE MANAGEMENT MARKET FOR THERAPEUTICS, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 16. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET FOR TISSUE PLASMINOGEN ACTIVATOR, 2016-2023 ($MILLION)
FIGURE 17. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET FOR ANTICOAGULANT, 2016-2023 ($MILLION)
FIGURE 18. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET FOR ANTIPLATELET, 2016-2023 ($MILLION)
FIGURE 19. GLOBAL THERAPEUTICS STROKE MANAGEMENT MARKET FOR ANTIHYPERTENSIVE, 2016-2023 ($MILLION)
FIGURE 20. STROKE MANAGEMENT MARKET FOR ISCHEMIC STROKE, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 21. STROKE MANAGEMENT MARKET FOR HEMORRHAGIC STROKE, BY COUNTRY, 2016-2023 ($MILLION)
FIGURE 22. GENERAL GOVERNMENT EXPENDITURE ON HEALTH AS A PERCENTAGE OF TOTAL GOVERNMENT EXPENDITURE
FIGURE 23. U.S. STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 24. CANADA STROKE MANAGEMENT MARKET, 2016-2023 $MILLION)
FIGURE 25. MEXICO STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 26. GERMANY STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 27. FRANCE STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 28. UK STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 29. ITALY STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 30. SPAIN STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 31. REST OF EUROPE STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 32. GDP OF ASIAN COUNTRIES ($BILLION)
FIGURE 33. JAPAN STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 34. CHINA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 35. AUSTRALIA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 36. INDIA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 37. SOUTH KOREA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 38. TAIWAN STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 40. BRAZIL STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 41. TURKEY STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 42. SAUDI ARABIA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 43. SOUTH AFRICA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 44. REST OF LAMEA STROKE MANAGEMENT MARKET, 2016-2023 ($MILLION)
FIGURE 45. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 46. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 47. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 48. B BRAUN: NET SALES, 2014-2016 ($MILLION)
FIGURE 49. B BRAUN: REVENUE SHARE BY PRODUCT, 2016 (%)
FIGURE 50. B BRAUN: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 51. BOSTON SCIENTIFIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 52. BOSTON SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 53. BOSTON SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 54. BRISTOL-MYERS SQUIBB: NET SALES, 2014-2016 ($MILLION)
FIGURE 55. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 56. BRISTOL-MYERS SQUIBB: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 57. CARDINAL HEALTH: NET SALES, 2014-2016 ($MILLION)
FIGURE 58. CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 59. GE HEALTHCARE: NET SALES, 2014-2016 ($MILLION)
FIGURE 60. GE HEALTHCARE: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 61. GE HEALTHCARE: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 62. GSK: NET SALES, 2014-2016 ($MILLION)
FIGURE 63. GSK: REVENUE SHARE BY SHARE, 2016 (%)
FIGURE 64. GSK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 65. MEDTRONIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 66. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 67. MEDTRONIC: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 68. MERCK: NET SALES, 2014-2016 ($MILLION)
FIGURE 69. MERCK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 70. MERCK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 71. SIEMENS: NET SALES, 2014-2016 ($MILLION)
FIGURE 72. SIEMENS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 73. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)